The Journal of Practical Medicine >

2025 , Vol. 41 >Issue 4: 615 - 620

DOI: https://doi.org/10.3969/j.issn.1006-5725.2025.04.023

Reviews

The biological role of YTHDF2 and its application in tumors

  • Dengxinjie SHI ,
  • Hongjin SHI ,
  • Nan ZHANG ,
  • Shi FU ,
  • Qun WANG ,
  • Haonan DONG ,
  • Jiansong WANG ,
  • Haidan LI ,
  • Haifeng. WANG
Expand
  • Department of Urology，the Second Affiliated Hospital of Kunming Medical University，Kunming 650000，Yunnan，China

Received date: 2024-11-14

  Online published: 2025-02-28

Fold

Abstract

YTHDF2 is a key m6A RNA modification "reader" that plays a crucial role in cell biological processes and tumor development. This review deeply explores the biological role of YTHDF2 and the advances in its application in tumors. The YTHDF2 structures are divided into mRNA procsomes and YTH domains， which recognize and bind m6A modified RNA molecules. It plays a biological role by promoting mRNA degradation， regulating cell signaling pathways and metabolism， and can regulate macrophage function and maintain an immunosuppressive state in the tumor microenvironment. YTHDF2 has the potential to serve as diagnostic markers， therapeutic targets and prognostic evaluation biomarkers in different tumors， but currently relevant studies are insufficient in sample size， molecular mechanism and clinical application. In the future， research can be conducted on comprehensive clinical research， in-depth analysis of molecular mechanisms， and research and development of optimized treatment strategies.

Key words： YTHDF2; m6A modification; biological role; tumor; diagnostic marker; therapeutic target; prognostic evaluation

Cite this article

Dengxinjie SHI , Hongjin SHI , Nan ZHANG , Shi FU , Qun WANG , Haonan DONG , Jiansong WANG , Haidan LI , Haifeng. WANG . The biological role of YTHDF2 and its application in tumors[J]. The Journal of Practical Medicine, 2025 , 41(4) : 615 -620 . DOI: 10.3969/j.issn.1006-5725.2025.04.023

References

1 CHEN Y， LIN Y， SHU Y， et al. Interaction between N6-methyladenosine （m6A） modification and noncoding RNAs in cancer［J］. Mol Cancer， 2020， 19（1 ）： 94. doi:10.1186/s12943-020-01207-4
2 DU H， ZHAO Y， HE J， et al. YTHDF2 destabilizes m6A-containing RNA through direct recruitment of the CCR4?NOT deadenylase complex［J］. Nat Commun， 2016， 7： 12626. doi:10.1038/ncomms12626
3 CHEN X， ZHOU X， WANG X. m6A binding protein YTHDF2 in cancer［J］. Exp Hematol Oncol， 2022， 11（1）： 21. doi:10.1186/s40164-022-00269-y
4 CARDELLI M， MARCHEGIANI F， CAVALLONE L， et al. A Polymorphism of the YTHDF2 Gene （1p35） Located in an Alu-Rich Genomic Domain Is Associated With Human Longevity［J］. J Gerontol A Biol Sci Med Sci， 2006， 61（6）： 547-556. doi:10.1093/gerona/61.6.547
5 WANG J Y， LU A Q. The biological function of m6A reader YTHDF2 and its role in human disease［J］. Cancer Cell Int， 2021， 21： 109. doi:10.1186/s12935-021-01807-0
6 JIN D， GUO J， WU Y， et al. m6A demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107/LATS2-mediated YAP activity in NSCLC［J］. Mol Cancer， 2020， 19（1）： 40. doi:10.1186/s12943-020-01161-1
7 EINSTEIN J M， PERELIS M， CHAIM I A， et al. Inhibition of YTHDF2 triggers proteotoxic cell death in MYC-driven breast cancer［J］. Mol Cell， 2021， 81（15）： 3048-3064.e9. doi:10.1016/j.molcel.2021.06.014
8 LI J， XIE H， YING Y， et al. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer［J］. Mol Cancer， 2020， 19（1）： 152. doi:10.1186/s12943-020-01267-6
9 CHEN Z， SHAO Y L， WANG L L， et al. YTHDF2 is a potential target of AML1/ETO-HIF1α loop-mediated cell proliferation in t（8；21） AML［J］. Oncogene， 2021， 40（22）： 3786-3798. doi:10.1038/s41388-021-01818-1
10 YAN J， HUANG X， ZHANG X， et al. LncRNA LINC00470 promotes the degradation of PTEN mRNA to facilitate malignant behavior in gastric cancer cells［J］. Biochem Biophys Res Commun， 2020， 521（4）： 887-893. doi:10.1016/j.bbrc.2019.11.016
11 YANG X， ZHANG S， HE C， et al. METTL14 suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XIST［J］. Mol Cancer， 2020，19（1）：46. doi:10.1186/s12943-020-1146-4
12 HOU J， ZHANG H， LIU J， et al. YTHDF2 reduction fuels inflammation and vascular abnormalization in hepatocellular carcinoma［J］. Mol Cancer， 2019， 18（1）： 163. doi:10.1186/s12943-019-1082-3
13 CHEN J， SUN Y， XU X， et al. YTH domain family 2 orchestrates epithelial-mesenchymal transition/proliferation dichotomy in pancreatic cancer cells［J］. Cell Cycle， 2017， 16（23）： 2259-2271. doi:10.1080/15384101.2017.1380125
14 WANG X， ZHANG J， WANG Y. Long noncoding RNA GAS5-AS1 suppresses growth and metastasis of cervical cancer by increasing GAS5 stability［J］. Am J Transl Res， 2019， 11（8）： 4909-4921.
15 DIXIT D， PRAGER B C， GIMPLE R C， et al. The RNA m6A Reader YTHDF2 Maintains Oncogene Expression and Is a Targetable Dependency in Glioblastoma Stem Cells［J］. Cancer Discov， 2021， 11（2）： 480-499. doi:10.1158/2159-8290.cd-20-0331
16 YU J， CHAI P， XIE M， et al. Histone lactylation drives oncogenesis by facilitating m6A reader protein YTHDF2 expression in ocular melanoma［J］. Genome Biol， 2021， 22（1）： 85. doi:10.1186/s13059-021-02308-z
17 WANG X， LU Z， GOMEZ A， et al. N6-methyladenosine-dependent regulation of messenger RNA stability［J］. Nature， 2014， 505（7481）： 117-120. doi:10.1038/nature12730
18 ZHU T， ROUNDTREE I A， WANG P， et al. Crystal structure of the YTH domain of YTHDF2 reveals mechanism for recognition of N6-methyladenosine［J］. Cell Res， 2014， 24（12）： 1493-1496. doi:10.1038/cr.2014.152
19 PARK O H， HA H， LEE Y， et al. Endoribonucleolytic Cleavage of m6A-Containing RNAs by RNase P/MRP Complex［J］. Mol Cell， 2019， 74（3）： 494-507.e8. doi:10.1016/j.molcel.2019.02.034
20 FEI Q， ZOU Z， ROUNDTREE I A， et al. YTHDF2 promotes mitotic entry and is regulated by cell cycle mediators［J］. PLoS Biol， 2020， 18（4）： e3000664. doi:10.1371/journal.pbio.3000664
21 LI H， ZHANG N， JIAO X， et al. Downregulation of microRNA-6125 promotes colorectal cancer growth through YTHDF2-dependent recognition of N6-methyladenosine-modified GSK3β［J］. Clin Transl Med， 2021， 11（10）： e602. doi:10.1002/ctm2.602
22 WANG W， SHAO F， YANG X， et al. METTL3 promotes tumour development by decreasing APC expression mediated by APC mRNA N6-methyladenosine-dependent YTHDF binding［J］. Nat Commun， 2021， 12（1）： 3803. doi:10.1038/s41467-021-24860-9
23 KORINEK V， BARKER N， MORIN P J， et al. Constitutive Transcriptional Activation by a β-Catenin-Tcf Complex in APC-/- Colon Carcinoma［J］. Science， 1997， 275（5307）： 1784-1787. doi:10.1126/science.275.5307.1784
24 YU P， XU T， MA W， et al. PRMT6-mediated transcriptional activation of ythdf2 promotes glioblastoma migration， invasion， and emt via the wnt-β-catenin pathway［J］. J Exp Clin Cancer Res， 2024， 43（1）： 116. doi:10.1186/s13046-024-03038-3
25 LIU R， LI W， TAO B， et al. Tyrosine phosphorylation activates 6-phosphogluconate dehydrogenase and promotes tumor growth and radiation resistance［J］. Nat Commun， 2019， 10（1）： 991. doi:10.1038/s41467-019-08921-8
26 SHENG H， LI Z， SU S， et al. YTH domain family 2 promotes lung cancer cell growth by facilitating 6-phosphogluconate dehydrogenase mRNA translation［J］. Carcinogenesis， 2020， 41（5）： 541-550. doi:10.1093/carcin/bgz152
27 ITALIANI P， BORASCHI D. From Monocytes to M1/M2 Macrophages： Phenotypical vs. Functional Differentiation［J］. Front Immunol， 2014， 5：514. doi:10.3389/fimmu.2014.00514
28 MA S， SUN B， DUAN S， et al. YTHDF2 orchestrates tumor-associated macrophage reprogramming and controls antitumor immunity through CD8+ T cells［J］. Nat Immunol， 2023， 24（2）： 255-266. doi:10.1038/s41590-022-01398-6
29 ZHANG L， DOU X， ZHENG Z， et al. YTHDF2/m6 A/NF-κB axis controls anti-tumor immunity by regulating intratumoral Tregs［J］. EMBO J， 2023， 42（15）： e113126. doi:10.15252/embj.2022113126
30 GRINBERG-BLEYER Y， CARON R， SEELEY J J， et al. The Alternative NF-κB Pathway in Regulatory T Cell Homeostasis and Suppressive Function［J］. J Immunol， 2018， 200（7）： 2362-2371. doi:10.4049/jimmunol.1800042
31 BETZLER A C， THEODORAKI M N， SCHULER P J， et al. NF-κB and Its Role in Checkpoint Control［J］. Int J Mol Sci， 2020， 21（11）： 3949. doi:10.3390/ijms21113949
32 张娅威， 施鸿金， 付什， 等. TIGIT的生物学作用及其在膀胱癌中应用的研究进展［J］. 实用医学杂志， 2024，40（12）： 1762-1766.
33 ZHANG L， LI Y， ZHOU L， et al. The m6A Reader YTHDF2 Promotes Bladder Cancer Progression by Suppressing RIG-I–Mediated Immune Response［J］. Cancer Res， 2023， 83（11）： 1834-1850. doi:10.1158/0008-5472.can-22-2485
34 王月帆， 葛春梅， 尹昊瓒， 等. m6A甲基化修饰识别蛋白YTHDF2在肝癌组织中的表达及临床意义［J］. 现代生物医学进展， 2021， 21（9）： 1601-1606.
35 胡宽，姚磊，李娟妮，等. YTH基因家族在肝癌中的表达和预后价值［J］. 中国普通外科杂志， 2021， 30（7）： 836-846.
36 马琰迪， 卢香云， 何尚峰， 等. m6A甲基化修饰结合蛋白YTHDF2在食管癌组织中的表达及其对食管癌细胞增殖和迁移的影响［J］. 吉林大学学报（医学版）， 2022， 48（4）： 962-970.
37 LIU W， LIU C， YOU J， et al. Pan-cancer analysis identifies YTHDF2 as an immunotherapeutic and prognostic biomarker［J］. Front Cell Dev Biol， 2022， 10： 954214. doi:10.3389/fcell.2022.954214
38 孟肖娜， 孙旭， 刘怀民. 免疫检查点抑制剂相关结肠炎的研究进展［J］. 实用医学杂志， 2024，40（9）： 1314-1319.
39 HUANG C S， ZHU Y Q， XU Q C， et al. YTHDF2 promotes intrahepatic cholangiocarcinoma progression and desensitises cisplatin treatment by increasing CDKN1B mRNA degradation［J］. Clin Transl Med， 2022， 12（6）： e848. doi:10.1002/ctm2.848
40 WANG L， DOU X， CHEN S， et al. YTHDF2 inhibition potentiates radiotherapy antitumor efficacy［J］. Cancer Cell， 2023， 41（7）： 1294-1308.e8. doi:10.1016/j.ccell.2023.04.019
41 SU G， LIU T， HAN X， et al. YTHDF2 is a Potential Biomarker and Associated with Immune Infiltration in Kidney Renal Clear Cell Carcinoma［J］. Front Pharmacol， 2021， 12： 709548. doi:10.3389/fphar.2021.709548
Options
Outlines

/

〈 〉